<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01616849</url>
  </required_header>
  <id_info>
    <org_study_id>PF-N-UMNPC</org_study_id>
    <nct_id>NCT01616849</nct_id>
  </id_info>
  <brief_title>Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma</brief_title>
  <official_title>Open-Label, Uncontrolled, Multicenter Phase II Study of Cisplatin and 5-Fu Combined With Nimotuzumab As First-Line Treatment in Patients With Untreated Metastatic Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital of Guangxi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hubei Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Provincial Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hangzhou Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangxi Provincial Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Cancer Hospital of Shantou University Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, uncontrolled, multicenter phase II clinical trial. The purpose of this&#xD;
      study is to evaluate acute toxicity and efficacy of cisplatin and 5-Fu combined with&#xD;
      nimotuzumab in patients with untreated metastatic nasopharyngeal carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>study period of 19 Months</time_frame>
    <description>To be determined by measurement of target lesions according to RECIST criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>19 Months</time_frame>
    <description>Defined as the time in months from first dose of Nimotuzumab until PD is observed or death occurs due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>19 Months</time_frame>
    <description>Defined as the time in months from first dose of Nimotuzumab to the date of death is observed or to last follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>8 Months</time_frame>
    <description>Using EORTC QLQ-C30(version 3.0) and EORTC QLQ-H&amp;N35(Version 1.0) to access the quality of life. Collecting data before treatment, 1 week after each 2 cycles of chemotherapy, 1 months after all treatment finished.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Stage IV Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>PF+ Nimotuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with cisplatin and 5-Fu combined with nimotuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin and 5-Fu combined with nimotuzumab</intervention_name>
    <description>DDP+5-Fu DDP 100 mg/m2 intravenous infusion in day1, 5-Fu 1000mg/m2/d continuous intravenous infusion on days 1 through 4, both drugs are given every 3 weeks.&#xD;
Nimotuzumab 200mg/d, intravenous infusion every week</description>
    <arm_group_label>PF+ Nimotuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic diagnosis of nasopharyngeal carcinoma&#xD;
&#xD;
          -  Distance metastasis at least 6 months after radical treatment&#xD;
&#xD;
          -  Not suitable for local treatment, e.g. surgery, TACE&#xD;
&#xD;
          -  At least one measurable lesion&#xD;
&#xD;
          -  Estimate survival &gt;3months&#xD;
&#xD;
          -  Range from 18～70 years old&#xD;
&#xD;
          -  PS 0~1&#xD;
&#xD;
          -  WBC count ≥ 4×109/L，Hemoglobin ≥ 100g/L， platelet count ≥ 100×109/L&#xD;
&#xD;
          -  ALT or AST &lt; 2.5×ULN、bilirubin &lt; 1.5×ULN&#xD;
&#xD;
          -  0Serum creatinine &lt; 1.5×ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Central nervous system metastases&#xD;
&#xD;
          -  Suitable for local treatment&#xD;
&#xD;
          -  Second malignancy within 5 years&#xD;
&#xD;
          -  Precious therapy with an investigational agent&#xD;
&#xD;
          -  Uncontrolled seizure disorder or other serious neurologic disease&#xD;
&#xD;
          -  ≥ Grade Ш allergic reaction to any drug including in this study&#xD;
&#xD;
          -  Clinically significant cardiac or respiratory disease&#xD;
&#xD;
          -  Creatinine clearance &lt; 30ml/min&#xD;
&#xD;
          -  Drug or alcohol addition&#xD;
&#xD;
          -  Do not have full capacity for civil acts&#xD;
&#xD;
          -  Severe complication, active infection&#xD;
&#xD;
          -  Concurrent immunotherapy or hormone therapy for other diseases&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chong Zhao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.sysucc.org.cn</url>
    <description>Home Page of Cancer Center, Sun Yat-sen University</description>
  </link>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>May 20, 2012</study_first_submitted>
  <study_first_submitted_qc>June 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2012</study_first_posted>
  <last_update_submitted>September 19, 2015</last_update_submitted>
  <last_update_submitted_qc>September 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhao Chong</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimotuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

